Novavax, Inc. (NASDAQ:NVAX) Shares Sold by PEAK6 Investments LLC

PEAK6 Investments LLC cut its holdings in Novavax, Inc. (NASDAQ:NVAX) by 41.9% during the third quarter, HoldingsChannel reports. The fund owned 23,000 shares of the biopharmaceutical company’s stock after selling 16,563 shares during the period. PEAK6 Investments LLC’s holdings in Novavax were worth $290,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in NVAX. Price T Rowe Associates Inc. MD lifted its holdings in Novavax by 17.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 56,065 shares of the biopharmaceutical company’s stock valued at $269,000 after acquiring an additional 8,128 shares during the last quarter. California State Teachers Retirement System lifted its stake in Novavax by 11.3% during the first quarter. California State Teachers Retirement System now owns 107,511 shares of the biopharmaceutical company’s stock worth $514,000 after purchasing an additional 10,949 shares in the last quarter. Tidal Investments LLC acquired a new position in Novavax during the first quarter worth $172,000. Baader Bank Aktiengesellschaft acquired a new position in Novavax during the second quarter worth $216,000. Finally, Bank of New York Mellon Corp lifted its stake in Novavax by 34.3% during the second quarter. Bank of New York Mellon Corp now owns 533,942 shares of the biopharmaceutical company’s stock worth $6,760,000 after purchasing an additional 136,472 shares in the last quarter. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. B. Riley restated a “buy” rating and set a $26.00 price target (up from $23.00) on shares of Novavax in a research note on Thursday, October 10th. HC Wainwright restated a “buy” rating and set a $19.00 price target on shares of Novavax in a research note on Tuesday, November 12th. Jefferies Financial Group decreased their price target on Novavax from $31.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday, October 16th. Finally, JPMorgan Chase & Co. increased their price objective on Novavax from $8.00 to $9.00 and gave the company an “underweight” rating in a research note on Monday, August 12th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $17.83.

Novavax Price Performance

NASDAQ:NVAX opened at $8.30 on Thursday. The firm has a market capitalization of $1.33 billion, a PE ratio of -3.67 and a beta of 2.02. The business’s fifty day moving average price is $10.15 and its 200 day moving average price is $12.46. Novavax, Inc. has a 12 month low of $3.53 and a 12 month high of $23.86.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.07. The firm had revenue of $84.51 million for the quarter, compared to analysts’ expectations of $65.80 million. The business’s revenue for the quarter was down 54.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.26) EPS. As a group, equities analysts anticipate that Novavax, Inc. will post -1.4 EPS for the current year.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.